CUE Cue Biopharma, Inc.
$21.16▲ +15.50%
Healthcare
Other
Volume 139.9K
Avg Volume (10D) 142.6K
Key Metrics & Fundamentals
Market Cap
$153.71M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.98 - 45.50
% vs 50 MA
-17.65%
% vs 200 MA
0.55%
RSI-14
47.4
MACD Histogram
+0.2600
Beta (1Y vs SPY)
2.84
Free Cash Flow
-$29.00M
Gross Rev
$7.88M
Gross Profit
$7.88M
EBITDA
-$177.14M
COGS
–
Operating Exp
$95.57M
Operating Income
-$87.70M
EBIT
-$87.70M
Pretax Income
-$153.07M
Net Income
-$153.07M
EPS (Diluted)
-24.14
Price & Volume History
Loading chart…
Recent News
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
MarketBeat · Sep 28, 2026 5:02 AM ET
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Insider Monkey · Sep 25, 2026 11:45 PM ET
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
BioPharma Dive · Sep 22, 2026 10:17 AM ET
Top Midday Decliners
MT Newswires · Sep 21, 2026 2:28 PM ET
Top Premarket Gainers
MT Newswires · Sep 21, 2026 7:02 AM ET
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
InvestorsHub · Sep 21, 2026 6:55 AM ET
Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate
MT Newswires · Sep 21, 2026 3:26 AM ET
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
GlobeNewswire · Sep 20, 2026 6:00 AM ET
Cue Biopharma Names James Ahlers CFO Following FDA Filing for CUE-221 in Food Allergy
MT Newswires · Aug 3, 2026 9:32 AM ET
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
GlobeNewswire · Aug 3, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See CUE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.